PHARMALEX: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMALEX
Largest movements
- Receivables within one year -€375,541
down €375,541 (-17.2%), from €2.2m to €1.8m
of which Trade receivables: -€311,459
- Cash +€109,310
up €109,310 (+33.9%), from €322,352 to €431,662
mainly Receivables within one year (+€375,541) and Net result for the year (+€64,882)
- Other debts -€197,516
down €197,516 (-81.3%), from €243,019 to €45,504
- Trade debts -€132,906
down €132,906 (-55.2%), from €240,640 to €107,734
of which Suppliers: -€132,398
- Tax, wage and social debts +€61,250
up €61,250 (+43.3%), from €141,522 to €202,773
of which Remuneration and social security: +€50,825
- Reserves +€33,107
up €33,107 (+1.8%), from €1.9m to €1.9m
of which Tax-exempt reserves: +€33,107
- Staff costs +€96,270
up €96,270 (+10.0%), from €960,238 to €1.1m
- Gross operating margin -€59,981
down €59,981 (-4.9%), from €1.2m to €1.2m
- Taxes -€47,949
down €47,949 (-58.5%), from €82,028 to €34,079
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,523,896 | €2,272,482 | -€251,414 | -10.0% |
| Fixed assets | 21/28 | €7,338 | €5,790 | -€1,548 | -21.1% |
| Tangible fixed assets | 22/27 | €7,338 | €5,790 | -€1,548 | -21.1% |
| Plant, machinery and equipment | 23 | €2,415 | €2,151 | -€264 | -10.9% |
| Furniture and vehicles | 24 | €4,923 | €3,639 | -€1,284 | -26.1% |
| Current assets | 29/58 | €2,516,558 | €2,266,692 | -€249,866 | -9.9% |
| Amounts receivable within one year | 40/41 | €2,180,202 | €1,804,661 | -€375,541 | -17.2% |
| Trade receivables | 40 | €939,768 | €628,309 | -€311,459 | -33.1% |
| Other amounts receivable | 41 | €1,240,434 | €1,176,352 | -€64,081 | -5.2% |
| Cash at bank and in hand | 54/58 | €322,352 | €431,662 | +€109,310 | +33.9% |
| Deferred charges and accrued income | 490/1 | €14,004 | €30,369 | +€16,365 | +116.9% |
| Total equity and liabilities | 10/49 | €2,523,896 | €2,272,482 | -€251,414 | -10.0% |
| Equity | 10/15 | €1,897,094 | €1,916,472 | +€19,378 | +1.0% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €1,857,700 | €1,890,807 | +€33,107 | +1.8% |
| Non-distributable reserves | 130/1 | €800,000 | €800,000 | = | 0.0% |
| Reserves not available under the articles | 1311 | €800,000 | €800,000 | = | 0.0% |
| Tax-exempt reserves | 132 | €126,300 | €159,407 | +€33,107 | +26.2% |
| Distributable reserves | 133 | €931,400 | €931,400 | = | 0.0% |
| Profit (loss) carried forward | 14 | €20,794 | €7,065 | -€13,729 | -66.0% |
| Amounts payable | 17/49 | €626,802 | €356,010 | -€270,792 | -43.2% |
| Amounts payable within one year | 42/48 | €626,802 | €356,010 | -€270,792 | -43.2% |
| Trade debts | 44 | €240,640 | €107,734 | -€132,906 | -55.2% |
| Suppliers | 440/4 | €240,132 | €107,734 | -€132,398 | -55.1% |
| Bills of exchange payable | 441 | €507 | - | -€507 | |
| Advances received on contracts in progress | 46 | €1,621 | - | -€1,621 | |
| Taxes, remuneration and social security | 45 | €141,522 | €202,773 | +€61,250 | +43.3% |
| Taxes | 450/3 | €41,364 | €51,789 | +€10,425 | +25.2% |
| Remuneration and social security | 454/9 | €100,159 | €150,984 | +€50,825 | +50.7% |
| Other amounts payable | 47/48 | €243,019 | €45,504 | -€197,516 | -81.3% |
| Remuneration, social security and pensions | 62 | €960,238 | €1,056,508 | +€96,270 | +10.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,512 | €1,548 | +€36 | +2.4% |
| Other operating charges | 640/8 | €975 | €6,112 | +€5,138 | +527.2% |
| Non-recurring operating charges | 66A | - | €3,000 | +€3,000 | |
| Gross operating margin | 9900 | €1,215,556 | €1,155,574 | -€59,981 | -4.9% |
| Operating profit (loss) | 9901 | €252,832 | €88,406 | -€164,426 | -65.0% |
| Financial income | 75/76B | €8,045 | €13,345 | +€5,300 | +65.9% |
| Recurring financial income | 75 | €8,045 | €13,345 | +€5,300 | +65.9% |
| Financial charges | 65/66B | €4,693 | €2,790 | -€1,903 | -40.6% |
| Recurring financial charges | 65 | €4,693 | €2,790 | -€1,903 | -40.6% |
| Profit (loss) for the period before taxes | 9903 | €256,183 | €98,961 | -€157,222 | -61.4% |
| Income taxes | 67/77 | €82,028 | €34,079 | -€47,949 | -58.5% |
| Profit (loss) for the period | 9904 | €174,155 | €64,882 | -€109,273 | -62.7% |
| Transfer from tax-exempt reserves | 789 | €89,000 | - | -€89,000 | |
| Transfer to tax-exempt reserves | 689 | €63,150 | €33,107 | -€30,043 | -47.6% |
| Profit (loss) for the period to be appropriated | 9905 | €200,005 | €31,775 | -€168,230 | -84.1% |
Source: filed annual accounts (NBB), fiscal years ended 30 June 2024 and 30 June 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 1 October 2026 via checked.be.